Status pages and timeline pages for investigational obesity compounds, built for questions where the answer changes as filings, readouts, and label decisions move.
FDA, EMA, MoHAP context plus trial-milestone summaries
Use case
Status questions, timeline queries, and filing-window comparisons
Framing
For Research Use Only — in-vitro laboratory research; not medical advice, diagnosis, treatment, or prevention
Quick answer — 2026 obesity-pipeline approval status
Retatrutide (LY-3437943, Eli Lilly) — Phase 3, not filed. TRIUMPH-1 pivotal topline May 21, 2026; TRIUMPH-2 and TRIUMPH-3 toplines July 23, 2026; U.S. BLA planned Q1 2027.
CagriSema (cagrilintide + semaglutide, Novo Nordisk) — Phase 3 REDEFINE programme; NDA filed with FDA in December 2025, decision pending.
Survodutide (BI 456906, Boehringer / Zealand) — Phase 3 SYNCHRONIZE programme; positive SYNCHRONIZE-1 obesity topline April 28, 2026 (16.6% mean weight loss at week 76). Not approved.
Orforglipron / Foundayo (Eli Lilly) — FDA approved as Foundayo (first oral non-peptide GLP-1, 2026); also UAE EDE approved in early April 2026.
Oral VK2735 (Viking Therapeutics) — Phase 2 complete, not approved; Phase 3 initiation expected Q4 2026. The subcutaneous VK2735 Phase 3 trials (VANQUISH-1 & -2) are fully enrolled, with readouts expected in 2027.
Already FDA approved: semaglutide (Wegovy injection, Wegovy pill, Wegovy HD 7.2 mg, Ozempic), tirzepatide (Zepbound/Mounjaro), and orforglipron (Foundayo). The European Commission approved the Wegovy pill + 7.2 mg pen July 15, 2026. Per-compound detail in the cards below or the 2026 master tracker.
Status Matrix
Current Approval and Evidence Snapshot
This table separates regulatory status from clinical-trial status. It is written for research and filing context only; it is not medical advice, prescribing guidance, or a human-use instruction.
Compound
Sponsor / programme
Status checked August 7, 2026
Primary evidence signal
Retatrutide
Eli Lilly / TRIUMPH
Investigational; TRIUMPH-1/-2/-3 toplines reported; no U.S. application filed; Lilly plans a BLA filing in Q1 2027 covering obesity, OSA, and knee osteoarthritis pain.
TRIUMPH-1 reported 28.3% mean body-weight reduction at 80 weeks on 12 mg in sponsor topline data.
CagriSema
Novo Nordisk / REDEFINE
FDA NDA filed December 2025; decision expected late 2026 (Novo guidance; potential 2027 launch)
REDEFINE-1 and related Phase 3 material support the filing; REDEFINE-4 adds head-to-head context.
Survodutide
Boehringer Ingelheim / Zealand / SYNCHRONIZE
Investigational; Phase 3 programme active; SYNCHRONIZE-2 completed with results reported October 1, 2026; no approval announced
SYNCHRONIZE-1 reported 16.6% mean body-weight reduction at week 76 in sponsor topline data.
Orforglipron / Foundayo
Eli Lilly / oral non-peptide GLP-1
FDA approved April 1, 2026; UAE EDE approval reported in April 2026
FDA label and Drugs@FDA record establish approved status and labelled tablet strengths.
Oral VK2735
Viking Therapeutics / VENTURE oral
Investigational; Phase 2 complete; Phase 3 initiation expected Q4 2026 per Viking’s July 29 corporate update
NCT06828055 tracks the oral dose-finding study; subcutaneous Phase 3 work is a separate programme.
What belongs in this cluster
This hub is for pages that answer a single freshness-sensitive question: approved or not, filed or not, when the next decision window is, and which programme milestone matters most right now. The goal is clarity rather than speculation.
Use the single-compound status pages when the query is specific to one asset.
Use the master trackers when the query spans multiple compounds or compares timelines.
Use the UAE trial-status page when a local clinical-trial question appears in the search path.
Core framing
Status first
These pages are written to answer whether a compound is approved, filed, in trial, or still investigational before any regional availability framing enters the page.
Direct answers to the most common 2026 obesity-pipeline approval questions, with deeper pages linked from each.
Which obesity drugs are FDA approved in 2026?
As of August 2026, FDA-approved obesity drugs include semaglutide (the Wegovy injection, Wegovy pill, and high-dose Wegovy HD 7.2 mg pen — plus Ozempic for T2D, all Novo Nordisk), tirzepatide (Zepbound/Mounjaro, Eli Lilly), and orforglipron (marketed as Foundayo, Eli Lilly) — the first oral non-peptide GLP-1. The European Commission approved the Wegovy pill and 7.2 mg pen on July 15, 2026. Retatrutide, CagriSema, Survodutide, and oral VK2735 remain investigational. Full timeline: 2026 obesity drug approval tracker.
Is retatrutide approved in 2026?
No. Retatrutide remains investigational and is not approved by the FDA, EMA, or UAE authorities. Lilly reported TRIUMPH-2 and TRIUMPH-3 topline results on July 23, 2026 and plans a U.S. BLA filing in Q1 2027; no application has yet been approved. Full status: is retatrutide approved?
Is CagriSema approved?
Not yet approved, but Novo Nordisk filed the CagriSema (cagrilintide + semaglutide) NDA with the FDA in December 2025 following the REDEFINE Phase 3 programme — REDEFINE 1 (obesity) and REDEFINE 2 (T2D) read out in 2025. FDA decision is pending as of August 2026, with Novo guidance pointing to a late-2026 decision window. Full status: is CagriSema approved?
Is Survodutide approved?
No. Survodutide (BI 456906, Boehringer Ingelheim / Zealand Pharma) is investigational. Boehringer reported positive SYNCHRONIZE-1 Phase 3 obesity topline on April 28, 2026, with 16.6% mean weight loss at week 76; SYNCHRONIZE T2D and additional readouts are ongoing. No U.S. application had been reported as of this review. Full status: is Survodutide approved?
Is Foundayo (orforglipron) approved?
Yes — on two regulators. Orforglipron was FDA approved as Foundayo in 2026, becoming the first oral non-peptide GLP-1 receptor agonist on the US market. The UAE Emirates Drug Establishment (EDE) approved orforglipron in early April 2026, marking a regional shift toward oral obesity treatment. Eli Lilly is the sponsor. Detail: Foundayo / orforglipron FDA approved.
When is retatrutide expected to be filed with the FDA?
Lilly stated on July 23, 2026 that it plans a U.S. Biologics License Application for retatrutide in Q1 2027 after completing the CMC package. No application has yet been approved. Tracker: TRIUMPH trial tracker.
Are any of these obesity drugs approved in the UAE?
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are registered with the UAE Ministry of Health and Prevention (MoHAP). Orforglipron (Foundayo) was approved by the UAE Emirates Drug Establishment (EDE) in early April 2026 — the first oral GLP-1 cleared for the UAE market. Retatrutide, CagriSema, Survodutide, and oral VK2735 are not registered in the UAE because they remain investigational worldwide. Regional context: UAE & GCC peptide guides · Orforglipron UAE price.
What is the difference between approved and investigational status?
Approved means a regulator (FDA, EMA, MoHAP) has authorised the drug for marketing after reviewing efficacy and safety data — labelled prescribing is permitted. Investigational means the drug is still in clinical trials or under regulatory review; it cannot be marketed for human use until approval. Investigational compounds may be available for in-vitro research only under Research Use Only frameworks.
Research Context
How to Read Approval Status Without Overstating the Data
Approval trackers are most useful when they keep four signals separate: regulator action, sponsor filing, trial-registry status, and peer-reviewed publication. A compound can have strong Phase 3 topline data and still be investigational; a submitted NDA can be under review without an announced public decision date; and a published trial can describe research findings without changing legal market status.
For this hub, "approved" means a named regulator has authorized a marketed product or label. FDA approval is checked against FDA announcements, Drugs@FDA, and product labelling. Clinical development status is checked against sponsor releases and ClinicalTrials.gov records. Trial data are treated as research context, not as medical, diagnostic, treatment, veterinary, or human-use guidance. Remy Peptides uses this page to organize public evidence for readers tracking the obesity-drug pipeline; any investigational compound discussed here remains outside labelled commercial drug use unless and until a regulator says otherwise.
That distinction matters for retatrutide and survodutide. Both have late-stage data signals in 2026, but neither has an announced FDA approval or public NDA approval. Retatrutide's TRIUMPH-1 topline is a pivotal Phase 3 obesity signal from Lilly, while the earlier Phase 2 publication in New England Journal of Medicine remains the peer-reviewed anchor for mechanism and dose-response context. Survodutide's SYNCHRONIZE-1 topline adds a Phase 3 dual GLP-1/glucagon signal, while MASH-focused trials remain a separate development pathway. These are programme milestones, not permission statements.
CagriSema sits in a different bucket because Novo Nordisk has publicly reported a US filing. Filing status is not approval status: it means the sponsor has submitted an application package for regulatory review. The REDEFINE clinical programme, PubMed-indexed REDEFINE analyses, and ClinicalTrials.gov records explain the evidence base, while the page's status answer remains "pending" until an FDA decision is public. Orforglipron / Foundayo is the approved-status contrast case in this cluster because the FDA has published an approval announcement and label for the oral non-peptide GLP-1 product.
For Research Use Only sourcing decisions, the practical takeaway is narrower than the clinical pipeline story. Researchers should document the compound name, sponsor code, current regulatory status, trial identifier, batch identity, COA status, and institutional handling requirements before any in-vitro laboratory work. The compounds tracked here are covered individually across the Research Use Only peptide library, each with its own evidence page and citation set. This page does not recommend, instruct, or imply use in humans or animals. It is an evidence map for tracking filings and trial milestones across Remy Peptides' research library.
Sources
References
Primary and registry sources used for the approval-status table and trial-context summaries.
U.S. Food and Drug Administration. FDA approves Foundayo (orforglipron) under the National Priority Voucher program. April 1, 2026. fda.gov
U.S. Food and Drug Administration. Foundayo (orforglipron) prescribing information, NDA 220934. accessdata.fda.gov
Emirates Drug Establishment. Foundayo / orforglipron UAE registration announcement. April 3, 2026. ede.gov.ae
Eli Lilly and Company. Retatrutide delivered topline results in the pivotal Phase 3 TRIUMPH-1 obesity trial. May 21, 2026. lilly.gcs-web.com
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity - a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
ClinicalTrials.gov. REDEFINE 1: CagriSema research study in overweight or obesity, NCT05567796. clinicaltrials.gov
Eli Lilly reported topline results from two additional Phase 3 retatrutide trials on July 23, 2026. In TRIUMPH-2 (1,152 adults with obesity or overweight and type 2 diabetes; 80 weeks), the company reported mean weight reductions of 12.7% at 4 mg, 19.1% at 9 mg, and 20.8% at 12 mg, with A1C reductions up to 1.6 percentage points. In TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease; 80 weeks), mean weight reduction reached 21.6% at 9 mg and 22.6% at 12 mg versus 3.2% on placebo. These are company-reported topline findings, not a head-to-head comparison; detailed TRIUMPH-2 results were published by Lilly on September 29, 2026 and presented at EASD, with TRIUMPH-3 to follow at a future meeting.
Lilly also stated that it plans a U.S. Biologics License Application in Q1 2027 after completing the chemistry, manufacturing, and controls package; the company's Q2 2026 report (August 5) states the clinical data package is complete to support global registrations in obesity, obstructive sleep apnea, and knee osteoarthritis pain. Retatrutide remains investigational and no application has yet been approved. Primary source: Eli Lilly, July 23, 2026.
FDA PCAC votes July 23–24, 2026: six peptides recommended
The FDA Pharmacy Compounding Advisory Committee concluded its July 23–24, 2026 meeting by voting to recommend six of the seven candidate peptides for the 503A Bulks List, in free base and acetate forms where applicable: BPC-157 (8–6, one abstention; evaluated use: ulcerative colitis), KPV (8–6, one abstention; wound healing and inflammatory conditions), TB-500 (8–6, one abstention; wound healing), MOTS-c (7–5, two abstentions; obesity and osteoporosis), Epitalon (insomnia), and Semax (8–5, one abstention; cerebral ischemia, migraine, trigeminal neuralgia). Emideltide (DSIP) was the only candidate not recommended (6–7, one abstention).
The recommendations are advisory, and FDA’s own scientific review staff opposed inclusion of all seven peptides, so the agency may still depart from the committee. Formal notice-and-comment rulemaking — which commonly takes a year or more — must conclude before any 503A list change takes effect. No compound gained an approved indication, and the votes do not change the research-only status of any research-grade peptide. Sources: FDA meeting page and materials; McDermott Will & Schulte meeting analysis. Full tallies and rulemaking outlook: PCAC explainer.
Evidence update — October 6, 2026
TRIUMPH-2: Lilly published detailed results on September 29, 2026, alongside the EASD presentation and a Lancet publication. The reported 20.8% mean weight reduction at 80 weeks with 12 mg is an efficacy-estimand result in adults with obesity or overweight and type 2 diabetes. Retatrutide remains investigational; Lilly retained its planned Q1 2027 US BLA submission. Lilly primary source.
SYNCHRONIZE-2: Results were reported October 1, 2026. In adults with obesity or overweight and type 2 diabetes, weight reduction reached 13.1% versus 3.1% with placebo at 76 weeks using the efficacy estimand. GI-related adverse events led to discontinuation in 18% versus 1.2% with placebo. These results concern a different population from SYNCHRONIZE-1 and are not a head-to-head comparison. Survodutide remains investigational and unapproved. Boehringer Ingelheim primary source.
This targeted update covers the sources above. Earlier review dates and historical update entries are retained; it is not a new review of every claim on this page.